$38.63
0.21% today
Nasdaq, Aug 22, 10:15 pm CET
ISIN
US30161Q1040
Symbol
EXEL

Exelixis, Inc. Stock price

$38.63
-5.84 13.13% 1M
+1.50 4.04% 6M
+5.33 16.01% YTD
+12.85 49.84% 1Y
+19.48 101.72% 3Y
+16.99 78.51% 5Y
+33.55 660.43% 10Y
+30.97 404.31% 20Y
Nasdaq, Closing price Fri, Aug 22 2025
-0.08 0.21%

Key metrics

Basic
Market capitalization
$10.4b
Enterprise Value
$9.6b
Net debt
positive
Cash
$791.1m
Shares outstanding
270.1m
Valuation (TTM | estimate)
P/E
18.3 | 13.4
P/S
4.7 | 3.9
EV/Sales
4.3 | 3.6
EV/FCF
12.8
P/B
5.1
Financial Health
Equity Ratio
76.1%
Return on Equity
23.2%
ROCE
32.1%
ROIC
34.3%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$2.2b | $2.7b
EBITDA
$781.5m | $1.1b
EBIT
$751.7m | $1.0b
Net Income
$602.3m | $779.6m
Free Cash Flow
$754.1m
Growth (TTM | estimate)
Revenue
10.7% | 23.7%
EBITDA
82.0% | 51.9%
EBIT
86.6% | 47.0%
Net Income
72.1% | 49.6%
Free Cash Flow
171.7%
Margin (TTM | estimate)
Gross
96.6%
EBITDA
35.1% | 40.7%
EBIT
33.7%
Net
27.0% | 29.1%
Free Cash Flow
33.8%
More
EPS
$2.1
FCF per Share
$2.8
Short interest
8.9%
Employees
1k
Rev per Employee
$1.9m
Show more

Is Exelixis, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Exelixis, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

26 Analysts have issued a Exelixis, Inc. forecast:

16x Buy
62%
10x Hold
38%

Analyst Opinions

26 Analysts have issued a Exelixis, Inc. forecast:

Buy
62%
Hold
38%

Financial data from Exelixis, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jul '25
+/-
%
2,230 2,230
11% 11%
100%
- Direct Costs 76 76
4% 4%
3%
2,154 2,154
11% 11%
97%
- Selling and Administrative Expenses 518 518
1% 1%
23%
- Research and Development Expense 884 884
13% 13%
40%
782 782
82% 82%
35%
- Depreciation and Amortization 30 30
12% 12%
1%
EBIT (Operating Income) EBIT 752 752
87% 87%
34%
Net Profit 602 602
72% 72%
27%

In millions USD.

Don't miss a Thing! We will send you all news about Exelixis, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Exelixis, Inc. Stock News

Positive
Seeking Alpha
22 days ago
EXEL continues to grow cabozantinib revenues while advancing zanzalintinib, but recent trial updates have been mixed and market reaction muted. STELLAR-303 has produced a success for zanzalintinib although the size of the clinical benefit isn't known yet. Zanzalintinib doesn't seem to have outperformed in head and neck cancer, with the company curtailing development in that indication following...
Neutral
Seeking Alpha
25 days ago
Exelixis, Inc. (NASDAQ:EXEL ) Q2 2025 Earnings Conference Call July 28, 2025 5:00 PM ET Company Participants l - Corporate Participant Amy C. Peterson - Executive VP of Product Development & Medical Affairs and Chief Medical Officer Christopher J.
Neutral
The Motley Fool
25 days ago
Exelixis Q2 Revenue Falls 11 Percent
More Exelixis, Inc. News

Company Profile

Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of Cometriq, Cabometyx, and Cotellic. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in Alameda, CA.

Head office United States
CEO Michael Morrissey
Employees 1,147
Founded 1994
Website www.exelixis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today